Article
What Is the State of the Union?
On this episode of Power and Market, we feel compelled to discuss this week's State of the Union speech.
aboutLiberty Portal
Liberty Portal is your gateway for free markets and free thinking. We aggregate open-sourced content to promote and popularize important people and lessons within the liberty movement.
suggested
Feb 23, 2026 / Dave DeCamp
US Evacuates Non-Emergency Personnel from Embassy in Beirut as it Prepares Potential Attack on Iran
The US has ordered the evacuation of non-emergency personnel and family members from its embassy in Beirut, Lebanon, as it prepares for a potential attack on Iran, which could provoke a full-blown regional war. A State Department official told The Hill that the evacuation was a “prudent” decision in response to the current security environment. […]
Read more
Feb 21, 2026 / Tyler Durden
Deporting Censorship: US Targets UK Government Ally Over Free Speech
Deporting Censorship: US Targets UK Government Ally Over Free Speech
Authored by Paul D. Thacker via RealClearInvestigations,
As ICE sweeps in Minneapolis have drawn wide attention, a little-noticed immigration case playing out in a New York federal court has significant implications for America’s relationship with Britain and the ongoing debate over global censorship.
In late December, the State Department announced its intention to revoke the visas of five foreign individuals who have allegedly censored Americans. The most consequential member of this group is Imran Ahmed, a British Labour Party political operative now...
Read more
Feb 23, 2026 / Tyler Durden
"Worst-Case Scenario": Novo Nordisk Plunges After Next-Gen Obesity Drug Falls Short Of Lilly Rival
"Worst-Case Scenario": Novo Nordisk Plunges After Next-Gen Obesity Drug Falls Short Of Lilly Rival
Shares of Novo Nordisk A/S plummeted again on Monday after the company reported trial results showing its next-generation obesity shot, CagriSema, delivered 20.2% weight loss at 84 weeks, compared to 23.6% for Eli Lilly & Co.’s tirzepatide (Zepbound).
Bloomberg Intelligence analyst Michael Shah explained, "This outcome is the worst-case scenario for Novo and heightens the need for M&A with Novo’s other GLP-1/Amylin drug."
Shares of Novo in Copenhagen plunged as much as 16.5%, breaking below a support level...
Read more


